"We are developing a program of work to support additional indications for Penthrox®. Our longer term ambition is to extend the use of Penthrox® into:
a. post-operative breakthrough pain;
b. breakthrough cancer pain;
c. repeat use scenarios; and ultimately
d. home use."
Ann: Annual Report to shareholders-MVP.AX, page-2
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MVP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
43.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $48.44M | |||
| Open | High | Low | Value | Volume |
| 43.0¢ | 44.0¢ | 43.0¢ | $6.872K | 15.74K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 28506 | 43.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.0¢ | 6327 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MVP (ASX) Chart |